Robert Beckman, M.D. is an oncology clinical researcher and biomathematician focused on improving the way cancer therapies are developed and utilized. He has co-invented novel clinical strategies for proof of concept studies, basket trials, and biomarker driven clinical development, as well as novel therapeutic strategies incorporating tumor evolution. In a previous 18 year industry career, he played leadership roles in forming 4 oncology clinical research groups. He has contributed approximately 300 published articles, book chapters, and presentations, emphasizing quantitative approaches to basic and applied oncology, including a recent book on master protocols. He currently leads the DahShu Innovative Design Scientific Working Group.

Fanni Natanegara is a Senior Director and Head for the Japan Statistics team at Eli Lilly and Company responsible for staff development, technical direction as well as strategic planning and execution of statistical deliverables to meet Japan regulatory and post-launch needs. She joined Lilly in 2003 after she obtained her PhD in Statistics from Baylor University. She held various statistical and leadership positions spanning across drug development phases and therapeutic areas. She is actively engaged in external professional organizations including serving as past Chairs of the Bayesian Scientific Working Group and the American Statistical Associations Statistical Partnership among Academe, Industry, and Government committee.

Zoran Antonijevic is Vice President of Statistical Consulting at Abond CRO. He held executive positions in Pharmaceutical Companies and CROs and has designed more than 100 clinical trials in numerous therapeutic areas, many of which included adaptive designs. Zoran is a long-time Chair and leader of the DIA Innovative Designs Scientific Working Group. He has authored numerous papers and scientific presentations and was editor of books “Optimization of Pharmaceutical R&D Programs and Portfolios” and, with Bob Beckman, “Platform Trials in Drug Development: Umbrella Trials and Basket Trials”.

Cristiana Mayer is the Head of Biostatistics at Johnson & Johnson Vision, a company dedicated to the eye care, eye health and eye products. She has 20+ years of experience in the pharmaceutical industry. After 18 years in drug development at Janssen R&D LLC working in different therapeutic areas and 5 years in Statistical Modeling & Methodology group, Cristiana is currently leading the biostatistics and data management groups across the Surgical and Vision Care businesses of JNJ Vision. Her current interests are in CID, Bayesian designs and patients’ engagement. Her recent publications are about simulation practices for innovative designs, ethics and innovation in the pandemic and patient engagement in rare diseases.

Dr. Price is the Deputy Director of the Office of Biostatistics. In her role at FDA, she promotes collaborative efforts to advance the use of complex innovative trial designs. An invited speaker at conferences world-wide, she has served as Chair of ASA’s Biopharmaceutical Section and on the Regional Committee of the Eastern North American Region of IBS. She is a Fellow of the ASA and the President-Elect of the ASA. With an MS in Biostatistics from UNC, and PhD from Emory, her research interests focus on clinical trial designs. She has co-authored papers in Statistics in Medicine, Clinical Trials, and Statistics in Biopharmaceutical Research.

Karen received her Ph.D. in Statistics from Baylor University in 2001, and joined Eli Lilly and Company at that time. She is currently Research Fellow at Eli Lilly and Company where she leads the Statistical Innovation Center, a team that focuses on innovative design and analysis of clinical trials. In 2011, Karen helped form and led the DIA Bayesian Scientific Working Group and currently serves as past-chair. This group includes members in Industry, Regulatory, and Academia. Her research interests include Bayesian design and analysis of clinical trials and master protocols. In 2016, Karen was elected a Fellow of the American Statistical Association.

Pritibha Singh, a leader at Novartis data42, brings 17 years of global experience spanning Switzerland, Germany, the United Kingdom, Australia, and New Zealand with extensive cross-sector experience (Tech space, Pharmaceutical, Biosimilar, Academia, FMCG, and Banking). Her expertise covers diverse therapeutic areas, including Cardiovascular, Diabetes, Neuroscience, Respiratory, Oncology, Immunology, and Hematology, with a comprehensive background in discovery, development, and late-phase. A blend of expertise in Drug Development (Psychology, Statistics, and Business). Currently pursuing a Doctorate (Dr. sc. ETH Zurich), specializing in sustainable strategies for decentralized clinical trials.

Rui (Sammi) Tang, PhD is currently the VP, Global Head of Biometric Oncology, leading Global biostatistics, statistical Programming and US Medical Writing Departments at Servier Pharmaceuticals US. Her research interests are primarily in adaptive clinical trial design and statistical issues in precision medicine. She authored more than 40 articles in peer-reviewed scientific journals on methodology, study design, data analysis and reporting and is a co-inventor of several patents. She is a co-founder of DahShu, a non-profit organization, founded to promote research and education of 5000 members. She is an active member in ASA and ICSA.

Amy Xia is Vice President, Center for Design and Analysis at Amgen. Amy has worked on designing, implementing, and analyzing Phase I-IV clinical trials as well as observational studies over the past two decades. Currently, she heads up the Center for Design and Analysis organization which includes Biostatistics, Design & Innovation and Data Sciences at Amgen, providing leadership and holistic vision for strategic drug development and driving innovative approaches across Amgen’s portfolios for evidence generation and decision-making. Amy received her PhD in Biostatistics from the University of Minnesota, and her medical degree from Peking University, China.

Maria Apostolaros is currently a Deputy VP of Science and Regulatory Advocacy at PhRMA in DC, the US industry association representing the country’s leading innovative biopharmaceutical research companies devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. In this role, she currently leads PhRMA’s regulatory policy initiatives on patient-focused drug development, clinical trial diversity, pharmacovigilance, innovative clinical trials, and clinical development. Maria completed her JD at the University of Maryland School of Law with a focus on health law, Dr of Pharmacy at Temple University, and an MS at Drexel. Maria is a Certified Compliance an Ethics Professional.

Yi Liu is Vice President of Biometrics at Nektar Therapeutics leading Biostatistics and Statistical Programming functions. Prior to that, she lead the statistical methodological group at Takeda designing and implementing innovative designs in multiple pivotal trials. Her research interests include multiple comparisons, adaptive designs, and issues with efficacy estimands for time-to-event endpoints. She is in the leadership team of the DIA Innovative Designs Scientific Working Group.